Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated
drug–drug interactions (DDIs) in vivo. The overall aim of our study was to investigate the …

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug–
drug interactions between digoxin and P-gp inhibitors (eg verapamil and its metabolite …

Inhibition of P-glycoprotein (PGP) resulting from the co-administration of substrate drugs
represents a potential source of drug–drug interactions. Although in vitro screens can readily …

To support drug development and registration, Caco-2 cell monolayer assays have
previously been set up and validated to determine whether candidate drugs are substrates …

Regulatory interest is increasing for drug transporters generally and P-glycoprotein (Pgp) in
particular, primarily in the area of drug–drug interactions. To aid in both identifying and …

Purpose. The objectives of this work were to evaluate the importance of moderate passive
permeability on apparent P-glycoprotein (P-gp) kinetics, and demonstrate that inspection of …

As one of the key components in model‐informed drug discovery and development,
physiologically‐based pharmacokinetic (PBPK) modeling linked with in vitro‐to‐in vivo …

ABSTRACT P‐glycoprotein (P‐gp)‐based drug interactions are a major concern in the clinic
and in preclinical drug development, especially with respect to the intestinal absorption of …

The efficacy of central nervous system (CNS) drugs may be limited by their poor ability to
cross the blood-brain barrier (BBB). Transporters, such as p-glycoprotein, may affect the …

Background The expression and activity of P-glycoproteins due to genetic or environmental
factors may have a significant impact on drug disposition, drug effectiveness or drug toxicity …